Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03061539
Title Nivolumab and Ipilimumab Treatment in Prostate Cancer With an Immunogenic Signature
Recruitment Recruiting
Gender male
Phase Phase II
Variant Requirements No
Sponsors University College, London

prostate adenocarcinoma


Ipilimumab + Nivolumab

Age Groups: adult | senior
Covered Countries

No variant requirements are available.